General Toxicity Notes
May cause excessive sedation in ESRD.
Excreted Unchanged %
40 (as drug or DCL)
Half-Life (Normalesrd) Hours
8-24 (DCL 28)/No change
Plasma Protein Binding %
97-99
Volume Of Distribution L/Kg
40-160
Dose For Normal Renal Function
10 mg q24h
Adjustment For Renal Failure Method
I
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
q24h [A]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
q24-48h [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
q48h [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Dose for GFR <10, [A]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Dose for GFR <10, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: No adjustment if clearance is 2000 mL/min, [D]
References
Hilbert J, Radwanski E, Weglein R, Luc V, Perentesis G, Symchowicz S, et al. Pharmacokinetics and dose proportionality of loratadine. J Clin Pharmacol. 1987; 27: 694-8. [PMID: 2960701] / Matzke GR, Halstenson CE, Opsahl JA, Hilbert J, Perentesis G, Radwanski E, et al. Pharmacokinetics of loratadine in patients with renal insufficiency. J Clin Pharmacol. 1990; 30: 364-71. [PMID: 2140371]
Toxicity Notes
Metabolized by cytochrome P450 (CYP3A4 and CYP2D6). Primary metabolite, decarboethoxy-loratadine (DCL), is active. Although the half-life is not changed in renal failure, AUC is increased. Significant drug interactions.